TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8459986
Drug: Metoclopramide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide plus dexamethasone (3 mg/kg i.v. x 2 and 20 mg i.v.)
Study: 24754070
Drug: Intravenous Idrinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Idrinol 1000 mg/day for 10-14 days (Group 1)
Study: 24754070
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy of coronary heart disease (Group 2)
Study: 28865098
Drug: Acotiamide 300
Normalized name: acetiamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acotiamide 300 mg/day + rabeprazole 10 mg/day
Study: 27982344
Drug: Late open
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late open lung strategy (L-OLS)
Study: 23688323
Drug: Dupilumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab (300 mg) administered subcutaneously once weekly for 12 weeks
Study: 23688323
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously once weekly for 12 weeks
Study: 20090438
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of intraperitoneal lidocaine
Study: 18171451
Drug: 50% dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% dose + placebo
Study: 18171451
Drug: 50% dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% dose
Study: 18171451
Drug: Baseline (100%)
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline (100%) dose
Study: 10908209
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus coumarins
Study: 8757358
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing of gentamicin or tobramycin (4 mg/kg IV)
Study: 8757358
Drug: Pharmacokinetic dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetic dosing (initial dose of 2 mg/kg IV every 12 hours)
Study: 8757358
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing and pharmacokinetic dosing of aminoglycosides
Study: 17429316
Drug: Perphenazine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perphenazine (0.1 mg/kg)
Study: 11561215
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of 50% sunflower oil (1.5 g/kg) followed by FSIVGTT 4 h later (test 2)
Study: 11561215
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of 50% sunflower oil (1.5 g/kg) with i.v. addition of 100 U/kg heparin prior to FSIVGTT (test 3)
Study: 11561215
Drug: Control (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (test 1: FSIVGTT, 0.3 g/kg glucose)
Study: 11561215
Drug: Heparin-induced high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-induced high levels of FFA (test 3)
Study: 9743819
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate (CS) 800 mg per day
Study: 25601227
Drug: Physiologic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic saline solution (placebo control)
Study: 21040582
Drug: Ambrotose AO®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrotose AO® (4 capsules per day = 2 grams per day)
Study: 18706769
Drug: Nicotine medications
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine medications
Study: 2183804
Drug: Auranofin (0.15-0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auranofin (0.15-0.20 mg/kg/day)
Study: 7307563
Drug: Triple gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple gel (sequential application of Keralyt, Estar, and Topsyn gels)
Study: 31741068
Drug: Ultrasound-guided bilateral
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided bilateral serratus plane block with 0.25% bupivacaine 30 ml each side
Study: 31741068
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received bilateral ultrasound-guided 2 ml 0.9% saline subcutaneously each block side
Study: 28143456
Drug: Liraglutide 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.2 mg in combination with metformin 1000 mg BID
Study: 28143456
Drug: Liraglutide 3
Normalized name: liraglutide 3.6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 3 mg QD alone
Study: 25590472
Drug: Internal intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal intradermal suturing
Study: 25590472
Drug: External intradermal
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External intradermal suturing
Study: 21455122
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (multicomponent lifestyle intervention)
Study: 11495047
Drug: Cerivastatin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.1 mg d(-1)
Study: 11495047
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg d(-1)
Study: 7824425
Drug: Capsaicin cream
Normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin Cream]
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin cream 0.025% applied twice daily
Study: 2901565
Drug: Naloxone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (30 micrograms/kg intravenous bolus followed by 30 micrograms/kg/h infusion)
Study: 2901565
Drug: Placebo (equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (equivalent volume bolus and infusion)
Study: 28008691
Drug: FAP therapist
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAP therapist training (FAPTT) course, eight weekly sessions
Study: 26228365
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (Esomeprazole 20 mg bid for 10 days, amoxicillin 1000 mg for 5 days, then clarithromycin 500 mg and tinidazole 500 mg; both bid for 5 days)
Study: 26228365
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (Esomeprazole 20 mg, clarithromycin 500 mg, and amoxicillin 1000 mg each bid for 14 days)
Study: 20966901
Drug: Solid protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid protein meal (steamed chicken breast + 750 ml water)
Study: 20966901
Drug: Liquefied protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquefied protein meal (steamed chicken breast blended in 500 ml water + 250 ml water)
Study: 15216404
Drug: 1% brinzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% brinzolamide ophthalmic solution
Study: 7609294
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam 0.1 mg.kg‐1 90 min prior to arrival in the operating room (Control)
Study: 6789354
Drug: Flurazepam 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurazepam 45 mg
Study: 29251975
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment plus Contingency Management (STCM)
Study: 29251975
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment Alone (STA)
Study: 19328267
Drug: Juice containing
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juice containing 50 mg DHA daily for 6 weeks
Study: 19328267
Drug: Juice containing
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juice containing 100 mg DHA daily for 6 weeks
Study: 16939483
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine (10 ml of 4% lidocaine)
Study: 15312157
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 8 mg of 14C‐labelled TCC
Study: 15312157
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of TCC and M1
Study: 15312157
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of TCC vs. intramuscular administration
Study: 11745909
Drug: Andolast 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andolast 2 mg
Study: 11745909
Drug: Andolast 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andolast 4 mg
Study: 11745909
Drug: Andolast 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andolast 8 mg
Study: 11745909
Drug: Andolast (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andolast (all doses)
Study: 8329700
Drug: Hydroxyurea (primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (primary therapy)
Study: 8329700
Drug: Busulfan (primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Busulfan (primary therapy)
Study: 3546618
Drug: Maintenance BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance BCG therapy (six-weekly doses of BCG plus monthly BCG for 2 years)
Study: 3546618
Drug: Nonmaintenance BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonmaintenance BCG therapy (BCG weekly for 6 weeks)
Study: 7036300
Drug: Maintenance BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance BCG therapy
Study: 3546618
Drug: Nonmaintenance BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonmaintenance BCG therapy
Study: 3546618
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Maintenance and Nonmaintenance BCG therapy)
Study: 30630796
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of surgery, antibiotics, and wuwei xiaodu drink
Study: 30630796
Drug: Surgery and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery and antibiotics
Study: 26907482
Drug: Oral PPI
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PPI (30 mg lansoprazole twice a day)
Study: 26907482
Drug: Intravenous PPI
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PPI (120 mg pantoprazole)
Study: 25315828
Drug: CDP-choline 1000
Normalized name: CDP-choline
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP-choline 1000 mg
Study: 25315828
Drug: CDP-choline 500
Normalized name: CDP-choline
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP-choline 500 mg
Study: 20488328
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow-derived mononuclear cell (BM-MNC) infusion
Study: 11496617
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dolasetron given orally 45 minutes prior to induction of anaesthesia (group I)
Study: 11496617
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg dolasetron given intravenously during induction of anaesthesia (group II)
Study: 11496617
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg DHB given intravenously during induction of anaesthesia (group III)
Study: 9725117
Drug: Mecamylamine (2.5‐5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecamylamine (2.5‐5.0 mg twice per day)
Study: 2731601
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1 g daily for one week)
Study: 765079
Drug: Incision, curettage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incision, curettage and primary suture under systemic antibiotic cover
Study: 28627310
Drug: Cluster-level dynamic
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cluster-level dynamic treatment regimens
Study: 25296928
Drug: Osmotic-Release Oral
Normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Osmotic-Release Oral System Methylphenidate
Study: 21147422
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor muscle exercise combined with routine treatment
Study: 21147422
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment including electrotherapy and general exercises
Study: 9419398
Drug: Dietary iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary iron intake (averaged from self‐administered food frequency questionnaires, energy‐adjusted, categorized into quartiles)
Study: 9419398
Drug: Iron supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplements (limited examination)
Study: 26846471
Drug: Meloxicam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam (15 mg daily, 5 mg three times a day)
Study: 26846471
Drug: Meloxicam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam (15 mg daily, 5 mg three times a day) in patients without viral hepatitis (NBNC-HCC)
Study: 18178947
Drug: Bicarbonate/lactate-based (Bic/Lac)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate/lactate-based (Bic/Lac) solution
Study: 18178947
Drug: Conventional lactate-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional lactate-based (Lac) solution
Study: 16189338
Drug: Low-dose intrathecal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intrathecal morphine (6 microg x kg(‐1) per ideal body weight in 5 mL normal saline)
Study: 16189338
Drug: Low-dose intrathecal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intrathecal morphine
Study: 16189338
Drug: Intrathecal normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal normal saline (5 mL)
Study: 12499341
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (500 or 1000 mg/d)
Study: 10532104
Drug: Ondansetron (syrup)
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron (syrup) plus dexamethasone
Study: 10532104
Drug: Intravenous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ondansetron plus dexamethasone (per os)
Study: 2062873
Drug: Scopolamine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.6 mg p.o.)
Study: 2062873
Drug: Powdered ginger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powdered ginger (500 mg)
Study: 2062873
Drug: Powder ginger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder ginger (500 or 1,000 mg) or fresh ginger root (1,000 mg)
Study: 27093770
Drug: 2.7 mL
Normalized name: glycerin 2.8 GM per 2.7 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.7 mL of 2% mepivacaine with 1:100,000 epinephrine and 1 mL of 75 TRU/mL hyaluronidase
Study: 27093770
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 mL of saline)
Study: 26360979
Drug: Fasudil (2.67
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasudil (2.67 mmol/L)
Study: 26360979
Drug: Papaverine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaverine (1.0 mmol/L)
Study: 24286636
Drug: VG (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: VG (30 μmol/L each of verapamil and nitroglycerin)
Study: 18782643
Drug: Weekly LOC
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly LOC during the past six months
Study: 15700491
Drug: Doxazosin GITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin GITS 4 mg or 8 mg once daily
Study: 3743441
Drug: Isophane human
Normalized name: insulin isophane human semi-synthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isophane human insulin
Study: 3743441
Drug: Isophane pork
Normalized name: insulin isophane pork
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isophane pork insulin
Study: 3743441
Drug: Protamine-bound biosynthetic
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protamine-bound biosynthetic human insulin
Study: 3743441
Drug: Porcine preparations
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porcine preparations
Study: 31439338
Drug: OAC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC with antiplatelet therapy (APT)
Study: 31439338
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy (APT) alone
Study: 16440160
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) administered at 20 ng/kg per minute
Study: 12635120
Drug: Progressive resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive resistance training (three sets of eight isometric contractions, three times weekly for 12 weeks)
Study: 9338422
Drug: 25-ml Bioenervi
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-ml Bioenervi treatment (125 ml contained 25 ml Bioenervi)
Study: 9338422
Drug: 125-ml Bioenervi
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125-ml Bioenervi treatment (125 ml contained 125 ml Bioenervi)
Study: 9338422
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal milk whey) treatment
Study: 9338422
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (25-ml Bioenervi, 125-ml Bioenervi, and placebo)
Study: 29421993
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (30 mg Zn gluconate per day)
Study: 17284557
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of reasoning ability training and increased proximal training gain
Study: 11485054
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg Hypericum perforatum L. (St. John's Wort)
Study: 11485054
Drug: 1800 mg
Normalized name: glycerin 1800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800 mg Hypericum perforatum L. (St. John's Wort)
Study: 7841567
Drug: Predictive dosing
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predictive dosing
Study: 29597104
Drug: ImpACT (Improving
Approvals — FDA: no, EMA: no, PMDA: no
Description: ImpACT (Improving AIDS Care after Trauma) intervention; details on dosage and duration not specified
Study: 20573338
Drug: One‐Session Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: One‐Session Treatment (OST)
Study: 11494074
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg vardenafil
Study: 12535027
Drug: L-cysteine-HCl 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-cysteine-HCl 500 mg in two divided doses per day
Study: 10792120
Drug: Midazolam 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.03 mg/kg bolus followed by 0.015 mg/kg after 1.5, 3 and 4.5 h
Study: 8665630
Drug: Meperidine 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 0.8 mg.kg‐1
Study: 8665630
Drug: Meperidine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 0.4 mg.kg‐1 plus 1.5 ml of 0.5% heavy bupivacaine
Study: 8665630
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml of heavy bupivacaine 0.5%
Study: 1316574
Drug: Human leucocyte
Normalized name: Human leucocyte antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human leucocyte alpha-interferon treatment; specific dosage and duration not mentioned.
Study: 6415738
Drug: Piracetam 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam 2.4 g/day
Study: 417361
Drug: Piracetam 4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam 4.8 g/day
Study: 30351408
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccination (≥1 dose)
Study: 30351408
Drug: Complete vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete vaccination (all three doses)
Study: 29165853
Drug: PDMP opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDMP opioid prescriptions (at least one prescription in the past year)
Study: 29165853
Drug: PDMP opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDMP opioid prescriptions (≥4 prescriptions)
Study: 27695865
Drug: Minoxidil 5%
Normalized name: MINOXIDIL 5% SOLN,TOP
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minoxidil 5% topical foam, applied daily (1 ml) for 6 months
Study: 22658432
Drug: Topiramate 100
Normalized name: topiramate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 100 mg oral dose
Study: 9313600
Drug: Recombinant staphylokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant staphylokinase (two 15 mg doses, 30 minutes apart)
Study: 9313600
Drug: rTPA (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTPA (intravenous front‐loaded, weight‐adjusted administration over 90 minutes)
Study: 8420615
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1200 mg of calcium daily)
Study: 2742167
Drug: 7.5‐10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5‐10 mg of 0.5% hyperbaric bupivacaine (Group A)
Study: 2742167
Drug: 10‐12.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐12.5 mg of 0.5% hyperbaric bupivacaine (Group B)
Study: 25173761
Drug: Disodium folinate
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disodium folinate 20 mg/m(2)
Study: 25173761
Drug: Disodium folinate
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disodium folinate 200 mg/m(2)